(Q84904896)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Jessica A Hemminger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Amanda Ewart Toland

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Thomas J Scharschmidt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Joel L Mayerson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

William G Kraybill

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Denis C Guttridge

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

O Hans Iwenofu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

31 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

282-288

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936067%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/modpathol.2012.133

12 February 2020

exact match

0 references

cites work

Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Differential gene expression in liposarcoma, lipoma, and adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Cancer/testis-associated genes: identification, expression profile, and putative function

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Tumor antigen expression in melanoma varies according to antigen and stage

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Cancer/testis (CT) antigens: potential targets for immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021

Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.133

7 January 2021